After decades of studies, recent comments by the Trump administration sparked fear amongst people regarding the alleged link between acetaminophen, a pain relieving and fever reducing drug, and conditions such as attention deficit hyperactivity disorder and autism spectrum disorder.
On Sept. 22 President Donald Trump and Secretary of Health and Human Services Robert F. Kennedy Jr. came out with a statement to warn the American public, specifically pregnant mothers, against taking Tylenol, a brand name for acetaminophen, in a press conference.
“Taking tylenol is not good… Fight like hell not to take it,” commented Trump.
During this address, Trump claimed that the ingestion of Tylenol during pregnancy could be associated with an increased risk of autism in the child, but many scientific organizations have refuted this claim, as there has been no observed causative link between the two subjects.
In studies regarding health related subjects, there are countless factors at play, and only observing a singular component of an issue can often lead to a skewed picture of the science around it. Studies related to this topic have been largely inconsistent, and haven’t proven a causal link.
Brock Garcia ’26, who is conducting a biomedical project researching the statistical significance between acetaminophen and autism, explained, “Saying that Tylenol is the cause of birth and childhood developmental issues is not telling the whole story, because there’s so many other things that could be the case, such as sickness, disease, or drugs and alcohol.”
Some findings have suggested a link between acetaminophen exposure in utero and increased risk of ADHD and autism, such as in a study published by JAMA Psychiatry in 2019. This study assessed cord plasma biomarkers of fetal exposure to acetaminophen, and concluded with increased risk of said disorders.
However, other major studies have determined the opposite, such as one published by JAMA in 2024, which was a sibling-control study spanning over 24 years. This investigation concluded that acetaminophen use during pregnancy was not associated with risk of children’s intellectual disability, and previous associations discovered were likely due to familial confounding.
To form a definitive outcome on the causal link, greater reliability across the data needs to exist.
“If the direct answer was acetaminophen causes autism, there would be a lot more consistency across studies, but we don’t see that,” said Garcia.
With a topic such as this, it can display the rate at which misinformation spreads. Often, information can be presented in a way that frames it as conclusive evidence, when really the subject spans far wider than that, revealing a different story.
When presented with a scientific claim, especially regarding health and safety, assessing the issue from all aspects and checking whether there is sufficient basis of research can be useful in gaining proper understanding of the topic.
The Lawsuit Information Center and other legal information sites have responded to the public’s worry by pointing out that the Tylenol autism lawsuit has encountered numerous obstacles in federal court, with numerous cases being dismissed and presently pending appeal. The continuous legal uncertainty surrounding the claims is highlighted by these revisions. In the same way, scientific associations are stressing that there is no concrete link between acetaminophen use during pregnancy specifically to autism. Experts highly advise consumers to rely on reliable medical advice when making healthcare decisions as the legal procedures and scientific debates proceed.
Science instructor Colleen O’Rourke stated, “Stories, headlines, or social media posts which are phrased or presented in a way to try to get a heightened emotional reaction, especially anger or fear, are very, very often based on misconceptions or even straight lies. So if you see something in the media which elicits such a response, follow up with more research, or talk to someone who understands the topic better to get a fuller picture.”
